Investment Access II SICAV RAIF
33A, avenue J.F. Kennedy
L-1855 Luxembourg
RCS Luxemburg Nr. B 250449
(the „Company")
www.ubs.com

Notice to shareholders of Investment Access II SICAV RAIF

The shareholders of **Investment Access II SICAV RAIF** are hereby informed that the statutory annual general meeting held on **30 June 2025** could not deliberate on the proposed agenda items. The shareholders are hereby invited to the Second Annual General Meeting of the Company that will take place at 33A, avenue J.F. Kennedy, L-1855 Luxembourg on **28 July 2025 at 13.00 p.m. (Luxembourg time)** with the following agenda ("Annual General Meeting"):

AGENDA

1. Declaration of Conflicts of the Board of Directors
2. Report of the Board of Directors and of the Auditor
3. Approval of the annual accounts as of 31 December 2024
4. Decision on allocation of the results
5. Discharge to be given to the members of the Board of Directors
6. Discharge to be given to the Auditor
7. Statutory elections
8. Approval of Directors' fees for the financial year ended 31 December 2025
9. Auditor's mandate

The annual report and the Report of the Board of Directors is available free of charge during normal office hours at the registered office of the Company in Luxembourg. Each shareholder may request that the annual report and the Report of the Board of Directors are sent to him by sending an E-mail request to: sh-ubsl-as-domiciliation@ubs.com.

The majority at the Annual General Meeting shall be determined according to the shares issued and outstanding at midnight (Luxembourg time) five days prior to the Annual General Meeting (referred to as "Record Date"). There will be no requirement as to the quorum in order for the Annual General Meeting to validly deliberate and decide on the matters listed in the agenda; resolutions will be passed by the simple majority vote of the shares present or represented at the meeting. At the Annual General Meeting, each share entitles to one vote. The rights of the shareholders to attend the Annual General Meeting and to exercise the voting right attached to their shares are determined in accordance with the shares held at the Record Date.

If you cannot attend this meeting and if you want to be represented by the chairman of the Annual General Meeting, please return a proxy (a standard proxy form is attached to this notice), dated and signed by mail and/or e-mail at the latest five days prior to the Annual General Meeting (i.e. 23 July 2025) to the attention of the Domiciliation Agent: UBS Europe SE, Luxembourg Branch, 33A, avenue J.F. Kennedy, L-1855 Luxembourg (e-mail: sh-ubsl-as-domiciliation@ubs.com).

Upon receipt of the proxy, the shares will be blocked until the day after the Annual General Meeting. Without specific instruction in writing to the company secretary (see above for contact details), any valid proxy which was returned for attendance at the Annual General Meeting will remain valid in case of another shareholders' meeting of the Company with the same agenda ("referred to as "Adjourned General Meeting") if the conditions for its validity are still met at the record date of the Adjourned General Meeting (i.e. five days prior to the Adjourned General Meeting). Similar blocking procedures as for the Annual General Meeting would be followed for the Adjourned General Meeting.

A valid new proxy returned on time for the Adjourned General Meeting shall be deemed to constitute a revocation of any proxy returned with respect to the Annual General Meeting.

Shareholders, or their representatives, wishing to participate in the Annual General Meeting in person are requested to notify the Company of their attendance at least five days prior to the Annual General Meeting.

The proxy form will only be valid if it includes the shareholder's and his/her/its legal representative's first name, surname and number of shares held at the Record Date and official address and signature as well as voting instructions and is received in due time. Incomplete or erroneous proxy forms or proxy forms, which do not comply with the formalities described therein, will not be taken into account.

The Board of Directors